Literature DB >> 2821447

Long term results of transsphenoidal adenomectomy in patients with Cushing's disease.

T Nakane1, A Kuwayama, M Watanabe, T Takahashi, T Kato, K Ichihara, N Kageyama.   

Abstract

As part of an ongoing series, 100 patients with Cushing's disease underwent transsphenoidal operations. Pituitary adenomas were confirmed in 93 patients, and initial remission was achieved in 86 (92%) of them. Hypercortisolemia was not corrected in 7 patients, and in 4 this was due to invasive adenomas. These patients were subjected to irradiation, medical treatment, or both after operation. Only 7 of the 100 patients had no pituitary adenoma found at operation, and they obtained no clinical remission even after partial or subtotal hypophysectomy. Follow-up review, with an emphasis on endocrinological studies, was performed on these patients for a mean period of 38 months. Seventy-eight patients were in long term remission after operation and had restoration of noncorticotropic hormone secretion as well as pituitary-adrenal function. Recurrence was noted in 8 patients after 19 to 82 months in remission. In all of these patients, pituitary adenomas were verified by reoperation and no case of corticotrophic cell hyperplasia was noted. We conclude that late recurrence of Cushing's disease may occur after adenoma removal and is due to the regrowth of adenoma cells left behind in the peritumoral tissue at the first operation. In view of the overall remission rate, transsphenoidal adenomectomy is considered a highly effective treatment for Cushing's disease.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2821447     DOI: 10.1227/00006123-198708000-00015

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  22 in total

Review 1.  Characterization of persistent and recurrent Cushing's disease.

Authors:  Nina K Sundaram; Alessia Carluccio; Eliza B Geer
Journal:  Pituitary       Date:  2014-08       Impact factor: 4.107

Review 2.  Surgical management of Cushing's disease.

Authors:  Robert F Dallapiazza; Edward H Oldfield; John A Jane
Journal:  Pituitary       Date:  2015-04       Impact factor: 4.107

3.  Diagnosis and treatment of Cushing's syndrome. Cushing's syndrome: current clinical problems, symposium. Padova, October 19-20, 1990.

Authors: 
Journal:  J Endocrinol Invest       Date:  1992-03       Impact factor: 4.256

4.  Outcome of using the histological pseudocapsule as a surgical capsule in Cushing disease.

Authors:  Jay Jagannathan; Rene Smith; Hetty L DeVroom; Alexander O Vortmeyer; Constantine A Stratakis; Lynnette K Nieman; Edward H Oldfield
Journal:  J Neurosurg       Date:  2009-09       Impact factor: 5.115

Review 5.  The Treatment of Cushing's Disease.

Authors:  Rosario Pivonello; Monica De Leo; Alessia Cozzolino; Annamaria Colao
Journal:  Endocr Rev       Date:  2015-06-11       Impact factor: 19.871

6.  Recurrent Cushing's disease with low adrenal androgen production.

Authors:  R J Louard; R A Gelfand
Journal:  J Endocrinol Invest       Date:  1991-12       Impact factor: 4.256

7.  Pituitary tumor apoplexy in patients with Cushing's disease: endocrinologic and visual outcomes after transsphenoidal surgery.

Authors:  Osamah J Choudhry; Asad J Choudhry; Elkin A Nunez; Jean Anderson Eloy; William T Couldwell; Ivan S Ciric; James K Liu
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

8.  Endocrine outcome of endoscopic endonasal transsphenoidal surgery in functioning pituitary adenomas.

Authors:  Jai-Ho Choe; Kun-Soo Lee; Sin-Soo Jeun; Jin-Hee Cho; Yong-Kil Hong
Journal:  J Korean Neurosurg Soc       Date:  2008-09-30

9.  Role of bilateral adrenalectomy in Cushing's disease.

Authors:  G Favia; M Boscaro; F Lumachi; D F D'Amico
Journal:  World J Surg       Date:  1994 Jul-Aug       Impact factor: 3.352

Review 10.  An approach to the management of patients with residual Cushing's disease.

Authors:  Lewis S Blevins; Nader Sanai; Sandeep Kunwar; Jessica K Devin
Journal:  J Neurooncol       Date:  2009-04-19       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.